Ixekizumab Gets FDA Nod for Active Psoriatic Arthritis

Ixekizumab significantly improves symptoms of psoriatic arthritis in patients naive to prior biologic therapy and in patients who had failed prior to biologic therapy.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply